Foresight Diagnostics announced an expanded strategic collaboration with Allogene Therapeutics, Inc. to include the development of the Company's minimal residual disease (MRD) assay as a companion diagnostic to identify patients with large B-cell lymphoma (LBCL) for the treatment of cemacabtagene ansegedleucel (cema-cel) in Allogene's ALPHA3 clinical trial.

Under the strategic collaboration, Allogene and Foresight will work together to support the development of Foresight Diagnostics' MRD assay in the EU, UK, Canada and Australia in support of Allogene's clinical development of cema-cel.

Cema-cel is being studied in the groundbreaking randomized controlled pivotal ALPHA3 trial as part of a first-line (1L) treatment to improve the cure rate in patients with LBCL. In the ALPHA3 trial, patients who achieve remission following initial treatment but remain positive for MRD, identified by using Foresight CLARITY™ IUO assay, will have an opportunity to receive cema-cel as a one-time consolidation dose to prevent disease recurrence.

"We are excited about our expanded collaboration with Allogene which will enable development of our MRD assay beyond the U.S.," said Sandra Close, PhD, Foresight Diagnostics' Chief Operations and Compliance Officer. "This is an important milestone as we continue to support our biopharma partners implementing MRD-driven clinical trials globally."